CBT-001
Phase 3Small molecule
CBT-001 is one of 7 small molecule programs targeting Pterygium. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Pterygium
#DrugCompanyPhaseTrials
1Trexall
Jazz PharmaceuticalsApproved
Pred Forte
NovartisApproved
Mitosol
UUroGen Pharma Ltd.
Approved
CBT-001
CCloudbreak Therapeutics, LLC
Phase 3
Oxylone
AbbViePreclinical
Tripterygium
NNanjing University School of Medicine
Preclinical
Enteral Nutrition
JJagiellonian University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBT-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCloudbreak Therapeutics, LLC